16 Apr CKDSens, a new device to improve the follow-up of patients with chronic kidney diseases
Solutions provided by CKDSens: ease of use of biomarker monitoring
More than 90 million people in the European Union and about 37 million in the United States have chronic kidney disease, a disease with a very high incidence in the population that alters the function of the kidneys and that can have serious implications for health. Thus, the detection and preventive control of this silent disease is crucial since every year millions of those affected die prematurely.
The platform (CKDSens) allows monitoring of relevant biomarkers with a single drop of blood and provides results in only 5 minutes. It has been designed to be very easy to use both from the medical office and by the patients themselves.
Advantages for the control of chronic kidney diseases: reduction of waiting time and personalization
CDKSens aims to make it easier for patients to monitor their chronic kidney disease by reducing hospital waiting times by more than 20% and improving their quality of life. Additionally, monitoring of these relevant biomarkers may allow healthcare professionals to adjust and personalize prescribed treatments.
Technology value: the collaboration process between CreatSens Health and Eurecat
CreatSens Health is a spin-off from the Rovira i Virgili University focused on the development of innovative medical devices for better control of chronic kidney disease through remote measurement of relevant parameters, in a simpler way and adapted to home use.
The market need detected by CreatSens Health to improve the detection and preventive control of this disease and the addition of its own capabilities to Eurecat’s R&D capabilities have resulted in the valorization of the technology developed through a process technology transfer between the technology center and the company through a license agreement from Eurecat to CreatSens Health for the use and exploitation of the health platform and the manufacture of sensors.
In view to expanding the scope of collaboration, CreatSens Health and Eurecat continue to develop new diagnostic tests that benefit people and health professionals.
The direct technological contribution of Eurecat
Eurecat has contributed its own knowledge and technology in the development of specific sensors and the management platform for health. It is also accompanying CreatSens Health in the development and industrialization of the device.
The Digital Health, Functional Printing and Integrated Systems and Valorization teams participate directly in the development of CKDSens and in the technology transfer agreement.
This collaboration is enabling the complex and much-needed technology transfer process to become a tangible reality. Adding the talent and complicity of the teams of the Digital Health technological unit for the development of the health platform. From the technological unit Printed Electronics for the printing of sensors and their industrial scalability. And from the Valuation Area for the transfer process.
Lower risk of reaching the market with complex innovations, this is the main advantage of collaboration between companies and technology centers such as Eurecat
The technology center-company binomial multiplies the chances of success for bringing complex technological innovations to market faster with less risk. Combining the constant research effort and the necessary entrepreneurial impulse that results in an innovative market solution. With the support of public funding, progress is being made in developing an affordable product. Easy to use for the patient and that can be introduced in clinical practice.